|By Marketwired .||
|July 24, 2014 03:00 PM EDT||
LONDON, ONTARIO -- (Marketwired) -- 07/24/14 -- McKenzie Lake Lawyers, LLP and Morganti Legal, P.C. have filed a class action lawsuit against Abbott Laboratories Ltd., Abbott Products Inc., Abbott Products Canada Inc., and Abbvie Products LLC ("Abbott"), the makers and sellers of Androgel on June 26, 2014.
Androgel is approved in Canada, since 2002, for use in the treatment of low-testosterone conditions associated with hypogonadism. It is one form of testosterone replacement therapy: other forms include injections, patches and pills. Use of these testosterone replacement therapies have been linked to an increased risk of suffering heart attacks, blood clots, strokes and death. This is the first testosterone replacement therapy class action commenced in Canada.
The Androgel Claim alleges that Abbott knew or should have known of these risks and failed to warn the public. The lawsuit also claims Abbott aggressively marketed Androgel by misleading potential users about the prevalence and symptoms of low testosterone, along with the safety and efficacy of Androgel treatment, ultimately failing to protect users from serious, life-threatening, adverse medical events.
Andrew Morganti, of Morganti Legal, P.C. says, "We believe that through this lawsuit, Abbott will be required to explain to Canadian consumers what it knew about the risks associated with using Androgel and when it first became aware of those risks."
Matthew Baer, of McKenzie Lake Lawyers explains: "In this case, as in all of these types of cases, we are concerned about whether Canadians were adequately warned of the risks associated with using this product."
It is too early to quantify the value of class member claims, but it is anticipated that the amounts are significant. Canadians, who have experienced adverse events from using Androgel, or other testosterone replacement products, are encouraged to visit www.mckenzielake.com, call 1-844-672-5666, or e-mail [email protected] for more information.